MANAGEMENT CONFIRMS OUTLOOK FOR 2012
Waregem (Belgium) / Rotterdam (the Netherlands)[1], 12 October 2012 (7:30 a.m.) - In the third quarter of 2012, Arseus's consolidated turnover increased by 4.5% (5.1% at constant exchange rates) to €121.9 million. Organic growth amounted to 5.4% (6.0%). In the first nine months of 2012, consolidated turnover increased by 11.7% (11.8%) to €390.2 million. Organic growth amounted to 5.1% (5.2%).
The evolution of turnover[2] per division is as follows:
| x 1,000 euros | Q3 2012 | Q3 2011 | Total growth | Org. growth |
| Fagron | 65,536 | 61,251 | +7.0% | +8.7% |
| Arseus Dental | 34,908 | 34,536 | +1.1% | +1.1% |
| Arseus Medical | 12,353 | 12,629 | -2.2% | -2.2% |
| Corilus | 9,138 | 8,253 | +10.7% | +10.7% |
| Total | 121,935 | 116,669 | +4.5% | +5.4% |
| x 1,000 euros | 9M 2012 | 9M 2011 | Total growth | Org. growth |
| Fagron | 206,601 | 170,055 | +21.5% | +7.6% |
| Arseus Dental | 118,519 | 116,143 | +2.0% | +2.0% |
| Arseus Medical | 38,096 | 38,446 | -0.9% | -0.9% |
| Corilus | 26,990 | 24,759 | +9.0% | +9.0% |
| Total | 390,207 | 349,403 | +11.7% | +5.1% |
Ger van Jeveren, CEO of Arseus: 'In the third quarter of 2012, Arseus once again recorded a solid result, with organic growth of 5.4%. This illustrates the successful execution of our innovation strategy. The focus on our own brands and the development of innovative concepts and solutions with substantial added value has meant that Arseus has suffered little, if at all from the continually changing economic circumstances. We therefore are confident about the future and confirm the expectations we announced earlier for 2012 as a whole. For 2012, we expect healthy organic growth and profitability that is once again to grow faster than turnover.'
[1] This press release was sent out by Arseus NV and Arseus BV.
[2] Unaudited management figures.
Please open the link below for the full press release:
